(OTCQX: $CSLLY)
#CSLBehring is committing approximately $1.5 billion over the next five years to expand its U.S. plasma-derived therapy manufacturing, strengthening the American plasma supply chain, meeting rising demand for immunoglobulin treatments, and creating hundreds of high-quality jobs across its CSL Behring network.
https://prismmarketview.com/csl-commits-1-5-billion-to-strengthen-u-s-plasma-supply-chain/
CSL’s vaccine spinoff plans just caught a cold. The Seqirus separation has been delayed indefinitely due to weak flu shot uptake and market conditions. Details: https://www.stockspinoffs.com/2025/10/30/csl-delays-seqirus-spinoff-amid-slumping-vaccine-demand/ $CSLLY
$CSLLY to spin out its vaccine arm, $ CSL Seqirus, by mid-2026
3,000 job cuts • USD 700-770 M charge • A$750 M buyback
Will the spin unlock value — or invite execution risk?
Details 👉 https://www.stockspinoffs.com/2025/10/23/csl-seqirus-spinoff/
News Article U.S. Food and Drug Administration Approves CSL's ANDEMBRY (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start
https://marketwirenews.com/news-releases/u-s-food-and-drug-administration-approves-csl-s-ande-6800974205429602.html
$CSLLY
$CSLLY $CSLLY Nhttps://marketwirenews.com/news-releases/csl-vifor-and-travere-therapeutics-announce-swissmed-8036968104308380.html
ews out CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI (sparsentan) for the treatment of IgA Nephropathy
$HYPD $SHPH and $ANIP and $CSLLY and $GSK What is new and opportunity in $HYPD?
1 - Insider bought 1.5 million shares in July and paid 1 Million dollars
2 - Vanguard biggest institution in the world bought 5 million dollars for a call option
3 - First FDA MydCombi selling from April 2024, and they have a contract with Vision Source biggest Private Practice Optometrists in the USA and Canada. Vision Source multi a billion company.
4 - Second FDA's strongest eyedrop sales start the first of August and are expected to generate 15 to 40 million per quarter.
5 - 8 or 9 August earnings call, and it should be good.
6 - MicroPine and MicroLine are unmet need eyedrops for children and the result is coming in Q4 2024.
